{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:59:54Z","timestamp":1773673194137,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40487-026-00421-2","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:26:32Z","timestamp":1772209592000},"page":"429-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Response to: Letter to the Editor Regarding \u201cCost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician\u2019s Choice of Treatment in Spain\u201d"],"prefix":"10.1007","volume":"14","author":[{"given":"Virginia","family":"Lozano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Llinares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Halavacek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Ashman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2809-7399","authenticated-orcid":false,"given":"David","family":"Carcedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Encinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"421_CR1","doi-asserted-by":"publisher","unstructured":"Nimwegan K, et al. Letter to the editor. A response to \u201cCost-effectiveness of elranatamab versus current therapies for the management of patients with triple-class exposed, relapsed and refractory multiple myeloma, including other bispecific and physician\u2019s choice of treatment in Spain\u201d. Oncol Ther. 2026. https:\/\/doi.org\/10.1007\/s40487-026-00420-3.","DOI":"10.1007\/s40487-026-00420-3"},{"key":"421_CR2","unstructured":"Van de Donk N, et al. Preliminary recommendations for prevention and management of infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab based on experience from the MajesTEC\u20111 study. Presented by NWCJ van de Donk at the 20th International Myeloma Society (IMS) Annual Meeting: September 27\u201330, 2023; Athens, Greece."},{"key":"421_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"421_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","author":"A Lesokhin","year":"2023","unstructured":"Lesokhin A, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase\u00a02 MagnetisMM-3 trial results. Nat Med. 2023. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"key":"421_CR5","doi-asserted-by":"publisher","unstructured":"Van Nimwegen KJM, Van Sanden S, Ghilotti F, et al. Evaluating the impact of censoring on progression-free survival comparisons of BCMA-targeting bispecific antibodies in relapsed\/refractory multiple myeloma. Value Health. 2025;28(12):S63. https:\/\/doi.org\/10.1016\/j.jval.2025.09.210.","DOI":"10.1016\/j.jval.2025.09.210"},{"key":"421_CR6","doi-asserted-by":"crossref","unstructured":"Lesokhin A, et al. Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: a retrospective analysis from MagnetisMM-3. ASH Annual Meeting; 2025 Dec; San Diego, CA, USA. Abstract abs25-8338.","DOI":"10.1182\/blood-2025-2269"},{"key":"421_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-020-0368-0","volume":"17","author":"AJ Templeton","year":"2020","unstructured":"Templeton AJ, Amir E, Tannock IF. Informative censoring\u2014a neglected cause of bias in oncology trials. Nat Rev Clin Oncol. 2020;17:327\u201328.","journal-title":"Nat Rev Clin Oncol"},{"key":"421_CR8","unstructured":"Burke JM. Addressing informative censoring bias in clinical trials. Target Oncol. 2024. https:\/\/www.targetedonc.com\/view\/addressing-informative-censoring-bias-in-clinical-trials. Accessed 20 Jan 2026."},{"key":"421_CR9","doi-asserted-by":"crossref","unstructured":"Van de Donk NWCJ, et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16 suppl):Abstract 8011.","DOI":"10.1200\/JCO.2023.41.16_suppl.8011"},{"key":"421_CR10","doi-asserted-by":"crossref","unstructured":"Prince HM, et al. MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma. Presented at the 66th ASH Annual Meeting and Exposition; 2024 Dec 7\u201310; San Diego, CA, USA. Abstract P4738.","DOI":"10.1182\/blood-2024-208192"},{"issue":"2","key":"421_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40487-025-00333-7","volume":"13","author":"C Encinas","year":"2025","unstructured":"Encinas C, Lozano V, Hlavacek P, Llinares J, Toribio-Castell\u00f3 S, Carcedo D, As\u00eds-Montalt J, Mart\u00ednez-L\u00f3pez J. Cost-effectiveness of elranatamab versus current therapies for the management of patients with triple-class exposed, relapsed and refractory multiple myeloma, including other bispecific and physician's choice of treatment in Spain. Oncol Ther. 2025;13(2):381\u2013395. https:\/\/doi.org\/10.1007\/s40487-025-00333-7","journal-title":"Oncol Ther."},{"issue":"1","key":"421_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1080\/13696998.2025.2514909","volume":"28","author":"LN Gordan","year":"2025","unstructured":"Gordan LN, Bensimon AG, Mu F, et al. Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States. J Med Econ. 2025;28(1):910\u201320.","journal-title":"J Med Econ"},{"issue":"10","key":"421_CR13","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1080\/03007995.2024.2391553","volume":"40","author":"D Reece","year":"2024","unstructured":"Reece D, Diels J, Van Sanden S, et al. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed\/refractory multiple myeloma. Curr Med Res Opin. 2024;40(10):1769\u201383.","journal-title":"Curr Med Res Opin"},{"key":"421_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.06.014","author":"HC Lee","year":"2025","unstructured":"Lee HC, Bumma N, Richter J, et al. Indirect comparison of linvoseltamab versus teclistamab for the treatment of triple-class exposed relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2025. https:\/\/doi.org\/10.1016\/j.clml.2025.06.014.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"421_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/03007995.2022.2139052","volume":"39","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Schecter JM, et al. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2023;39(1):81\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"15","key":"421_CR16","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1200\/JCO.23.00225","volume":"41","author":"M Merino","year":"2023","unstructured":"Merino M, Kasamon Y, Theoret M, Pazdur R, Kluetz P, Gormley N. Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival. J Clin Oncol. 2023;41(15):2706\u201312 (Erratum in: J Clin Oncol, 2023; 41(27): p. 4449).","journal-title":"J Clin Oncol"},{"key":"421_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/JBM.S507550","volume":"16","author":"I Mol","year":"2025","unstructured":"Mol I, Hu Y, LeBlanc TW, et al. Matching-adjusted indirect comparison of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma: updated results. J Blood Med. 2025;16:233\u20139.","journal-title":"J Blood Med"},{"key":"421_CR18","unstructured":"National Institute for Health and Care Excellence. Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma: TA658. 2020."},{"key":"421_CR19","unstructured":"National Institute for Health and Care Excellence. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments: TA1023. 2024."},{"key":"421_CR20","unstructured":"European Medicines Agency. Elrexfio: summary of product characteristics [November 2025]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elrexfio-epar-product-information_en.pdf. Accessed 20 Jan 2026."},{"key":"421_CR21","unstructured":"European Medicines Agency. Tecvayli: summary of product characteristics. [November 2025]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf. Accessed 20 Jan 2026."},{"key":"421_CR22","doi-asserted-by":"publisher","unstructured":"Usmani SZ, Karlin L, Benboubker L, et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. J Clin Oncol . 2023;41(16):8034. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8034.","DOI":"10.1200\/JCO.2023.41.16_suppl.8034"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00421-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00421-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00421-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:44:39Z","timestamp":1773668679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00421-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["421"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00421-2","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Virginia Lozano, Julia Llinares, Patrick Hlavacek and Olivia Ashman are employees of Pfizer and may hold Pfizer stock. David Carcedo is employee of Hygeia Consulting. Joaqu\u00edn Mart\u00ednez-L\u00f3pez has received honoraria derived from research projects from Amgen, Incity, Janssen and Pfizer, and from lectures and participation in advisory boards from Amgen, BMS, Gilead, Incity, Janssen, Novartis, Pfizer and Roche. Cristina Encinas has received honoraria derived from lectures and participation in advisory boards from Amgen, BMS, GSK, Johnson and Johnson, Menarini Stemline, Sanofi and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This response letter is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Declarations"}}]}}